

Corrigendum to: LTBK-01. Updates On The Phase Ii And Re-treatment Study Of AZD6244 (Selumetinib) For Children With Recurrent Or Refractory Pediatric Low Grade Glioma: A Pediatric Brain Tumor Consortium (PBTC) Study

Jason R. Fangusaro¹, Arzu Onar-Thomas², Tina Young Poussaint³, Shengjie Wu², Azra H Ligon⁴, Neal Ian Lindeman⁴, Anuradha Banerjee⁵, Roger Packer⁶, Lindsay B. Kilburn⁶, Ian F. Pollack⁷, Ibrahim A. Qaddoumi², Paul Graham Fisher⁸, Girish Dhall⁹, Patricia Ann Baxter¹⁰, Susan G. Kreissman^{11,15}, L. Austin Doyle¹², Malcolm A. Smith¹², Maryam Fouladi¹³ and Ira J. Dunkel¹⁴

¹Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, USA, ²St. Jude Children's Research Hospital, Memphis, TN, USA, ³Children's Hospital Boston, Boston, MA, USA, ⁴Brigham and Women's Hospital, Boston, MA, USA, ⁵University of California, San Francisco, San Francisco, CA, USA, ⁶Children's National Health System, Washington, DC, USA, ⁷Pittsburgh Children's Hospital, Pittsburgh, PA, USA, ⁸Stanford University, Palo Alto, CA, USA, ⁹Children's Hospital Los Angeles, Los Angeles, CA, USA, ¹⁰Texas Children's Cancer Center, Baylor College of Medicine, Houston, TX, USA, ¹¹Duke University Medical Center, Durham, NC, USA, ¹²Cancer Therapy Evaluation Program, National Cancer Institute, Washington, DC, USA, ¹³Cincinnati Children's Hospital Medical Center, Cincinnati, OH, USA, ¹⁴Memorial Sloan Kettering Cancer Center, New York, NY, USA, ¹⁵Greenbaum Cancer Center, Baltimore, MD, USA

When this abstract was originally published, it contained the following erroneous text:

"Both stratum 2 (pilocytic astrocytoma [PA] without common BRAF aberration) and stratum 5 (non-pilocytic astrocytoma with BRAF aberration) met response criteria for expansion (> 2 objective responses in 16 patients), and accrual to a total of 25 patients on each stratum is ongoing."

This should have appeared as:

"Stratum 5 (non-pilocytic astrocytoma with BRAF aberration) met response criterion for expansion (≥ 2 objective responses in 16 patients) and accrual to a total goal of 25 patients

is ongoing. Stratum 2 (pilocytic astrocytoma [PA] without common BRAF aberration) has not met this same criterion for expansion, and accrual to a goal of 16 patients in Simon Stage 1 is ongoing."

The error occurred due an incorrect stratification of a subject. This subject had achieved a partial response, but a recent review of the data revealed that the subject should have been assigned to stratum 6 (indeterminate BRAF status) rather than to stratum 2.

These details have been corrected only in this corrigendum to preserve the published version of record.